CN101282981B - 膦酸化利福霉素及其在预防和治疗骨和关节感染中的用途 - Google Patents

膦酸化利福霉素及其在预防和治疗骨和关节感染中的用途 Download PDF

Info

Publication number
CN101282981B
CN101282981B CN2006800373829A CN200680037382A CN101282981B CN 101282981 B CN101282981 B CN 101282981B CN 2006800373829 A CN2006800373829 A CN 2006800373829A CN 200680037382 A CN200680037382 A CN 200680037382A CN 101282981 B CN101282981 B CN 101282981B
Authority
CN
China
Prior art keywords
compound
acid
group
bone
rifomycin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800373829A
Other languages
English (en)
Chinese (zh)
Other versions
CN101282981A (zh
Inventor
Y·S·罗斯
S·奇布拉
T·康
A·拉费法
E·迪特里希
Y·拉方丹
R·雷迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Targanta Therapeutics Inc
Original Assignee
Targanta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targanta Therapeutics Inc filed Critical Targanta Therapeutics Inc
Publication of CN101282981A publication Critical patent/CN101282981A/zh
Application granted granted Critical
Publication of CN101282981B publication Critical patent/CN101282981B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2006800373829A 2005-08-11 2006-08-11 膦酸化利福霉素及其在预防和治疗骨和关节感染中的用途 Expired - Fee Related CN101282981B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70714505P 2005-08-11 2005-08-11
US60/707,145 2005-08-11
PCT/IB2006/004128 WO2007096703A2 (en) 2005-08-11 2006-08-11 Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections

Publications (2)

Publication Number Publication Date
CN101282981A CN101282981A (zh) 2008-10-08
CN101282981B true CN101282981B (zh) 2012-09-26

Family

ID=38437733

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800373829A Expired - Fee Related CN101282981B (zh) 2005-08-11 2006-08-11 膦酸化利福霉素及其在预防和治疗骨和关节感染中的用途

Country Status (11)

Country Link
US (1) US8404664B2 (de)
EP (1) EP1928890B1 (de)
JP (1) JP5368092B2 (de)
KR (1) KR101327635B1 (de)
CN (1) CN101282981B (de)
AU (1) AU2006339058B2 (de)
BR (1) BRPI0614758A2 (de)
CA (1) CA2618741C (de)
EA (1) EA016059B1 (de)
IL (1) IL189270A (de)
WO (1) WO2007096703A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200809194A (en) * 2006-05-04 2008-02-16 Wyeth Corp Determination of antibiotic concentration in bone
WO2010019511A2 (en) * 2008-08-13 2010-02-18 Targanta Therapeutics Corp. Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections
CN103501819B (zh) * 2011-02-24 2016-08-17 Ktb肿瘤研究有限责任公司 二膦酸盐-前药
FR2973378B1 (fr) * 2011-03-28 2013-10-04 Atlanthera Derives d'acide hydroxybisphosphonique bifonctionnels
ES2793174T3 (es) * 2013-05-31 2020-11-13 Genentech Inc Anticuerpos antiteicoicos de pared y conjugados
EP3226911A1 (de) * 2014-12-03 2017-10-11 F.Hoffmann-La Roche Ag Antikörper gegen staphylococcus aureus mit rifamycinkonjugaten und verwendungen davon
BR112017011478A2 (pt) * 2014-12-03 2018-02-27 Genentech, Inc. composto de conjugado anticorpo-antibiótico, conjugado anticorpo-antibiótico, composição farmacêutica, métodos de tratamento de uma infecção bacteriana e para exterminar staph aureus, processo para a preparação do composto, kit e intermediário antibiótico-ligante
CN104524928A (zh) * 2014-12-30 2015-04-22 上海锅炉厂有限公司 一种捕集二氧化碳的吸收剂
CN107011380A (zh) * 2016-01-28 2017-08-04 臧伟 一种二膦酸衍生物及含二膦酸衍生物的组合物治疗骨折的应用
ES2868180T3 (es) * 2017-06-26 2021-10-21 Biofer Spa Derivados de pirido-imidazo rifamicina como agentes antibacterianos
CA3105829A1 (en) * 2018-07-09 2020-01-16 Biovinc, Llc. Bisphosphonate quinolone conjugates and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854227A (en) * 1994-03-04 1998-12-29 Hartmann; John F. Therapeutic derivatives of diphosphonates
US5880111A (en) * 1995-06-07 1999-03-09 Farcasiu; Dan Therapeutic derivations of diphosphonates
US6333424B1 (en) * 1996-10-09 2001-12-25 Eliza Nor Biopharmaceuticals, Inc. Therapeutic derivatives of diphosphonates
US6605609B2 (en) * 2000-06-16 2003-08-12 Pharmacia & Upjohn Company Thizaine oxazolidinone

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR208F (de) 1964-07-31
US4261891A (en) 1965-08-24 1981-04-14 Ciba-Geigy Corporation Antibiotically active rifamycin derivatives
GB1478563A (en) 1975-03-05 1977-07-06 Lepetit Spa Rifamycin derivatives
IT1056272B (it) 1975-06-13 1982-01-30 Archifar Ind Chim Trentino Prodotti derivati dalle amine aromatiche
AU536524B2 (en) * 1979-06-28 1984-05-10 Gruppo Lepetit S.P.A. Water soluble hydrozones of 3-formylifamyan
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
CA1304363C (en) 1988-11-01 1992-06-30 Takehiko Yamane 3'-hydroxybenzoxazinorifamycin derivative, process for preparing the same and antibacterial agent containing the same
JP2746041B2 (ja) * 1992-02-14 1998-04-28 三菱化学株式会社 新規なステロイド誘導体
JPH093080A (ja) * 1995-04-21 1997-01-07 Sumitomo Pharmaceut Co Ltd 新規な骨親和性エストロゲン誘導体
EP1511753A4 (de) 2001-09-06 2005-10-12 Activbiotics Inc Antimikrobielle mittel und ihre verwendung
US7122525B2 (en) 2001-11-21 2006-10-17 Activbiotics, Inc. Targeted therapeutics and uses thereof
AU2002364162A1 (en) 2001-12-13 2003-06-30 Activbiotics, Inc. Sulfhydryl rifamycins and uses thereof
WO2004096285A2 (en) * 2003-04-25 2004-11-11 Gilead Sciences, Inc. Anti-infective phosphonate conjugates
WO2005020894A2 (en) 2003-08-22 2005-03-10 Activbiotics, Inc. Rifamycin analogs and uses thereof
CA2550729A1 (en) 2003-12-23 2005-07-14 Activbiotics, Inc. Rifamycin analogs and uses thereof
EP1730154B1 (de) 2004-01-13 2012-10-17 Cumbre IP Ventures, L.P. Gegen arzneimittelresistente mikroben wirksame rifamycinderivate
EP1723150A1 (de) 2004-01-13 2006-11-22 Cumbre Pharmaceuticals Inc. Gegen arzneimittel resistente mikrobenwirksame rifamyciniminoderivate
US7256187B2 (en) 2004-03-10 2007-08-14 Cumbre Pharmaceuticals Inc. Rifamycin C-11 oxime derivatives effective against drug-resistant microbes
US7265107B2 (en) 2004-03-10 2007-09-04 Cumbre Pharmaceuticals Inc. Rifamycin C-11 oxime cyclo derivatives effective against drug-resistant microbes
US7250413B2 (en) 2004-04-26 2007-07-31 Cumbre Pharmaceuticals Inc. C-25 carbamate rifamycin derivatives with activity against drug-resistant microbes
US7202246B2 (en) 2004-06-09 2007-04-10 Cumbre Pharmaceuticals Inc. Spiro-rifamycin derivatives targeting RNA polymerase
US7229996B2 (en) 2004-07-22 2007-06-12 Cumbre Pharmaceuticals Inc. Rifamycin derivatives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854227A (en) * 1994-03-04 1998-12-29 Hartmann; John F. Therapeutic derivatives of diphosphonates
US5880111A (en) * 1995-06-07 1999-03-09 Farcasiu; Dan Therapeutic derivations of diphosphonates
US6333424B1 (en) * 1996-10-09 2001-12-25 Eliza Nor Biopharmaceuticals, Inc. Therapeutic derivatives of diphosphonates
US6605609B2 (en) * 2000-06-16 2003-08-12 Pharmacia & Upjohn Company Thizaine oxazolidinone

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Takehiko YAMANE et al..Synthesis and Biological Activity of 3"-Hydroxy-5"-aminobenzoxazinorifamycin Derivatives.《Chem.Pharm.Bull.》.1993,第41卷(第1期),第148-155页. *

Also Published As

Publication number Publication date
BRPI0614758A2 (pt) 2011-04-12
JP2009505974A (ja) 2009-02-12
IL189270A (en) 2015-05-31
CN101282981A (zh) 2008-10-08
US20110263534A1 (en) 2011-10-27
EA016059B1 (ru) 2012-01-30
KR101327635B1 (ko) 2013-11-12
EP1928890A4 (de) 2011-08-31
AU2006339058A1 (en) 2007-08-30
KR20080035687A (ko) 2008-04-23
WO2007096703A3 (en) 2008-01-03
EP1928890B1 (de) 2013-04-03
EP1928890A2 (de) 2008-06-11
EA200800570A1 (ru) 2009-02-27
US8404664B2 (en) 2013-03-26
IL189270A0 (en) 2008-08-07
CA2618741C (en) 2014-03-25
JP5368092B2 (ja) 2013-12-18
WO2007096703A2 (en) 2007-08-30
AU2006339058B2 (en) 2012-09-06
CA2618741A1 (en) 2007-08-30

Similar Documents

Publication Publication Date Title
CN101282981B (zh) 膦酸化利福霉素及其在预防和治疗骨和关节感染中的用途
US8524691B2 (en) Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections
JP2002511406A (ja) 感染症の治療および予防処置のための有機リン化合物の使用
WO2007138381A2 (en) Phosphonated oxazolidinones and uses thereof for the prevention and treatment of bone and joint infections
CN101945874A (zh) 作为抗癌剂的3-取代的-4-氧代-3,4-二氢-咪唑并[5,1-d][1,2,3,5]-四嗪-8-甲酰胺类
US8946144B2 (en) Phosphonated glycopeptide and lipoglycopeptide antibiotics and uses thereof for the prevention and treatment of bone and joint infections
JP3156794B2 (ja) 高水溶性メタロプロテイナーゼ阻害剤
CN101300248A (zh) 膦酸酯化的氟喹诺酮、其抗菌类似物以及预防和治疗骨和关节感染的方法
Tanaka et al. Bisphosphonated fluoroquinolone esters as osteotropic prodrugs for the prevention of osteomyelitis
JPH10500977A (ja) ピリジルビスホスホン酸エステルよりなる治療用活性薬剤
KR20000023709A (ko) 시스-치환된 아미노사이클로프로판 유도체
US6207655B1 (en) Bis-phosphonate confugates with alkylating moieties having antitumor activity
CN110981803B (zh) 一种抗肿瘤化合物及其合成方法与应用
WO1999033473A1 (fr) Remedes contre les maladies intramedullaires
KR20050018809A (ko) 펩티드 디포르밀라아제 활성화 프로드러그

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120926

Termination date: 20180811

CF01 Termination of patent right due to non-payment of annual fee